Hurwitz H - Search Results

1

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Hurwitz H, et al. N Engl J Med. 2004 Jun 3;350(23):2335-42. doi: 10.1056/NEJMoa032691. N Engl J Med. 2004. PMID: 15175435 Free article. Clinical Trial.

2

Complete response to neoadjuvant chemoradiation for rectal cancer does not influence survival.

Onaitis MW, Noone RB, Fields R, Hurwitz H, Morse M, Jowell P, McGrath K, Lee C, Anscher MS, Clary B, Mantyh C, Pappas TN, Ludwig K, Seigler HF, Tyler DS. Onaitis MW, et al. Among authors: hurwitz h. Ann Surg Oncol. 2001 Dec;8(10):801-6. doi: 10.1007/s10434-001-0801-2. Ann Surg Oncol. 2001. PMID: 11776494

3

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.

Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E. Kabbinavar F, et al. J Clin Oncol. 2003 Jan 1;21(1):60-5. doi: 10.1200/JCO.2003.10.066. J Clin Oncol. 2003. PMID: 12506171 Clinical Trial.

4

Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer.

Fernando NH, Hurwitz HI. Fernando NH, et al. Among authors: hurwitz hi. Semin Oncol. 2003 Jun;30(3 Suppl 6):39-50. doi: 10.1016/s0093-7754(03)00124-6. Semin Oncol. 2003. PMID: 12802794 Review.

5

A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon.

Czito BG, Hong TJ, Cohen DP, Tyler DS, Lee CG, Anscher MS, Ludwig KA, Seigler HF, Mantyh C, Morse MA, Lockhart AC, Petros WP, Honeycutt W, Spector NL, Ertel PJ, Mangum SG, Hurwitz HI. Czito BG, et al. Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):779-85. doi: 10.1016/S0360-3016(03)01567-0. Int J Radiat Oncol Biol Phys. 2004. PMID: 14967434 Clinical Trial.

6

Targeted therapy of colorectal cancer: clinical experience with bevacizumab.

Fernando NH, Hurwitz HI. Fernando NH, et al. Among authors: hurwitz hi. Oncologist. 2004;9 Suppl 1:11-8. doi: 10.1634/theoncologist.9-suppl_1-11. Oncologist. 2004. PMID: 15178811 Free article. Review.

7

Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma.

Blackwell K, Hurwitz H, Liebérman G, Novotny W, Snyder S, Dewhirst M, Greenberg C. Blackwell K, et al. Among authors: hurwitz h. Cancer. 2004 Jul 1;101(1):77-82. doi: 10.1002/cncr.20336. Cancer. 2004. PMID: 15221991 Free article. Clinical Trial.

8

Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer.

Hurwitz H. Hurwitz H. Clin Colorectal Cancer. 2004 Oct;4 Suppl 2:S62-8. doi: 10.3816/ccc.2004.s.010. Clin Colorectal Cancer. 2004. PMID: 15479481 Review.

9

Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer.

Collins TS, Hurwitz HI. Collins TS, et al. Semin Oncol. 2005 Feb;32(1):61-8. doi: 10.1053/j.seminoncol.2004.09.026. Semin Oncol. 2005. PMID: 15726507 Review.

10

New combinations in metastatic colorectal cancer: what are our expectations?

Hurwitz H. Hurwitz H. Oncologist. 2005 May;10(5):320-2. doi: 10.1634/theoncologist.10-5-320. Oncologist. 2005. PMID: 15851788 Free article. Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

271 results

Search Page